Thursday, September 5

3:45–4:45 pm

Navigating 131I-MIBG and CAR T 19, in COG trials ANBL1531 and AALL1721: Sharing Care and Strategies for Success (C205)

coglogoThe Children’s Oncology Group (COG) is committed to improving outcomes for pediatric oncology patients with the high-risk disease through clinical trials. Despite tremendous advancements in pediatric oncology treatment, survival in two patient populations remains inferior. Patients with high-risk neuroblastoma have a projected 3-year event-free survival of 73% (Park et al., 2016), and patients with precursor B lineage acute lymphoblastic leukemia with positive minimal residual disease at the end of consolidation have a projected 5-year disease-free survival of 39% (Borowitz et al., 2015).

5:00–6:00 pm

Infant ALL: Rearranged for the Big Screen! Providing Care on COG AALL15P1, Nurses in a Leading Role! (C211)

coglogoAcute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with 5-year overall survival rates exceeding 90% (Hunger, Lu, Devidas, Camitta, Gaynon, Winick, 2012). Unfortunately, infants with ALL are an exception to the improving survival trends and remain one of the most challenging populations in pediatric hematology/oncology (Kotecha, Gottardo, Kees, Cole, 2014).